NCT00418860已完成不适用
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Incidence of definite stent thrombosis by Academic Research Consortium Proposed Standard
研究概览
简要总结
The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or stent thrombosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with clinically significant de novo coronary artery disease
- •Stenting only with Endeavor® stents
- •The sum of stent length is less than 60 mm for one lesion. The sum of stent length in multiple lesions does not matter.
排除标准
- •Cardiogenic shock
- •ST-elevation myocardial infarction within 48 hours of symptom onset
- •Prior implantation of drug-eluting stents
- •Left ventricular dysfunction (echocardiographic left ventricular ejection fraction < 25%)
- •Stenting both branch of bifurcation lesion
- •Left main trunk lesion
- •Graft vessels
- •Patients who have to receive clopidogrel due to other conditions
- •Patients who have to receive warfarin, cilostazol or other antiplatelet therapy
- •Patient with chronic renal failure (S-Cr > 2.0 mg/dl)
- •Hypersensitivity to clopidogrel or aspirin
- •Expectant survival less than 1 year
- •Women who plan to become pregnant
- •Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)
- •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
研究组 & 干预措施
A
Experimental
干预措施: Aspirin, Clopidogrel (Drug)
结局指标
主要结局
Incidence of definite stent thrombosis by Academic Research Consortium Proposed Standard
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent ImplantationStent ThrombosisCoronary Artery DiseaseMyocardial IschemiaNCT00822536Assistance Publique - Hôpitaux de Paris1,798
进行中（未招募）
不适用
Optimal duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms: A prospective randomized multicenter trialDiseases of the circulatory systemKCT0006651Seoul National University Bundang Hospital528
进行中（未招募）
1 期
Optimal duration of dual anti-platelet therapy in patients undergoing endovascular revascularization of the superficial femoral artery.Patients with diagnosis of lower limbs PAOD, ranging from stage 2 to 5 according to Rutherford classification and lesions of the SFA treated by endovascular revascularizationMedDRA version: 20.0Level: LLTClassification code 10016430Term: Femoral artery stenosisSystem Organ Class: 100000004866EUCTR2018-000532-94-ITFONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO78
招募中
不适用
Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk PatientsCarotid Artery DiseasesNCT06276374Woo-Keun Seo1,556
已完成
4 期
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 StudyCoronary Artery DiseaseNCT02619760Kyoto University, Graduate School of Medicine3,045